Thomas E. Hughes

President & Chief Executive Officer at Navitor Pharmaceuticals, Inc.

Thomas E. Hughes

Thomas E. Hughes

President & Chief Executive Officer at Navitor Pharmaceuticals, Inc.

Overview
Career Highlights

Navitor Pharmaceuticals, Inc.
Zafgen, Inc.

RelSci Relationships

1107

Number of Boards

8

Birthday

1960

Age

60

Contact Data
Trying to get in touch with Thomas E. Hughes? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Thomas E. Hughes likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Rodin Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Miragen Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Zafgen, Inc.

Relationship likelihood: Strong

Founder at Good2Go LLC

Relationship likelihood: Strong

Scientific Founder at Navitor Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Remeditex Ventures LLC

Relationship likelihood: Strong

Managing Member at Care Capital III LLC

Relationship likelihood: Strong

Co-Founder at Third Rock Ventures LLC

Relationship likelihood: Strong

Venture Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Chief Scientific Officer & Co-Founder at Relay Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Thomas E. Hughes
Potential Connections via
Relationship Science
You
Thomas E. Hughes
President & Chief Executive Officer at Navitor Pharmaceuticals, Inc.
Education
Ph.D. in Nutrition

Tufts University is a private research university located in Medford/Somerville, near Boston, in the U.S. state of Massachusetts. The university is organized into ten schools, including two undergraduate programs and eight graduate divisions, on four campuses in Massachusetts and the French Alps. The university emphasizes active citizenship and public service in all of its disciplines and is known for its internationalism and study abroad programs.

B.A. in Biology

Franklin & Marshall was established in 1787 with a gift of 200 British pounds from Benjamin Franklin, and is located in historic Lancaster, a dynamic city with a thriving arts scene. The College enrolls 2,324 students. The average class size is 19 students, and the student-faculty ratio is 9:1. Our students receive more than $500,000 in research grants every year.

M.S. in Zoology

Virginia Tech takes a hands-on, engaging approach to education, preparing scholars to be leaders in their fields and communities. As the commonwealth’s most comprehensive university and its leading research institution, Virginia Tech offers 215 undergraduate and graduate degree programs to more than 30,000 students and manages a research portfolio of more than $450 million. The university fulfills its land-grant mission of transforming knowledge to practice through technological leadership and by fueling economic growth and job creation locally, regionally, and across Virginia.

BA Biology

Franklin University and its branch campus Urbana University are student-centered, nonprofit, independent institutions providing high quality, relevant education to enable the broadest possible community of learners to achieve their goals and enrich the world.

Career History
President, Chief Executive Officer & Director
2008 - 2018

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Global Head, Diabetes Research
1987 - 2008

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Advisor
Current

Atlas Venture focuses on investments in early-stage companies operating in the fields of biotechnology. The firm partners with entrepreneurs to build companies around innovative science.

Boards & Committees
Member, Board of Directors
2018 - Current

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell's response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.

Member, Board of Directors
2017 - Current

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Scientific Advisory Board Member
Current

Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

Navitor Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Zafgen, Inc. raised money in a private placement transaction

Details Hidden

Zafgen, Inc. raised money in a private placement transaction

Investments
Details Hidden

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Thomas E. Hughes. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Thomas E. Hughes's profile does not indicate a business or promotional relationship of any kind between RelSci and Thomas E. Hughes.